Author:
Melling Nathaniel,Grass Julia,Reeh Matthias,Tachezy Michael,Blessmann Marco,Nickel Felix,Hackert Thilo,Grupp Katharina
Abstract
Abstract
Background
Prolyl hydroxylase 1 (PHD1) is a prognostic marker in several cancers.
Aims and scopes
This study was undertaken to elucidate the clinical relevance of PHD1 in colorectal cancer (CRC) prognosis.
Materials and methods
We compared PHD1 expression on a tissue microarray (TMA) containing samples from 1800 CRCs with corresponding clinicopathological tumor variables and patient survival.
Results
While PHD1 staining was always high in benign colorectal epithelium, high PHD1 staining was detectable in only 71.8% of CRCs. Low PHD1 staining was associated with advanced tumor stage (p = 0.0101) and shortened overall survival in CRC patients (p = 0.0011). In a multivariable analysis including tumor stage, histological type and PHD1 staining revealed tumor stage and histological type (p < 0.0001 each), but also PHD1 staining (p = 0.0202) to be independent prognostic markers for CRC.
Conclusions
In our cohort, loss of PHD1 expression independently identified a subset of CRC patients with poor overall survival and might, thus, be a promising prognostic marker. PHD1 targeting may even allow for specific therapeutic approaches for these patients.
Funder
Universitätsklinikum Hamburg-Eppendorf (UKE)
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine